| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Fujigotemba Research Laboratories, Chugai Pharmaceutical Company, Gotemba, Japan.
1. Allosteric potentiation of the ionotropic quisqualate (iQA) receptor by a nootropic drug aniracetam (1-p-anisoyl-2-pyrrolidinone) was investigated using Xenopus oocytes injected with rat brain mRNA and rat hippocampal slices. 2. Aniracetam potentiates the iQA responses induced in Xenopus oocytes by rat brain mRNA in a reversible manner. This effect was observed above the concentrations of 0.1 mM. Kainate. N-methyl-D-aspartate and gamma-aminobutyric acid responses induced in the same oocytes were not affected. 3. The specific potentiation of iQA responses was accompanied by an increase in the conductance change of iQA and alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) responses, but the affinity of receptors for agonist and the ion-selectivity of the channels (reversal potentials) were not changed. 4. Aniracetam reversibly potentiated the iQA responses recorded intracellularly from the pyramidal cells in the CA1 region of rat hippocampal slices. The excitatory postsynaptic potentials (EPSPs) in Schaffer collateral-commissural-CA1 synapses were also potentiated by aniracetam. 5. Population EPSPs recorded in the mossy fibre-CA3 synapses as well as Schaffer-commissural synapses were also potentiated by aniracetam. The amplitudes of the potentiation were not changed by the formation of long-term potentiation.
This article has been cited by other articles:
|
|
 |
|
  S. S. Jhee, A. S. Chappell, V. Zarotsky, S. V. Moran, M. Rosenthal, E. Kim, S. Chalon, N. Toublanc, J. Brandt, D. E. Coutant, et al. Multiple-Dose Plasma Pharmacokinetic and Safety Study of LY450108 and LY451395 (AMPA Receptor Potentiators) and Their Concentration in Cerebrospinal Fluid in Healthy Human Subjects. J. Clin. Pharmacol., April 1, 2006; 46(4): 424 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bourasset, K. Bernard, C. Munoz, P. Genissel, and J.-M. Scherrmann NEUROPHARMACOKINETICS OF A NEW {alpha}-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLE PROPIONIC ACID (AMPA) MODULATOR, S18986 [(S)-2,3-DIHYDRO-[3,4]CYCLOPENTANO-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE], IN THE RAT Drug Metab. Dispos., August 1, 2005; 33(8): 1137 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S.F. Ling and L. S. Benardo Nootropic Agents Enhance the Recruitment of Fast GABAA Inhibition in Rat Neocortex Cereb Cortex, July 1, 2005; 15(7): 921 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Arai, Y.-F. Xia, G. Rogers, G. Lynch, and M. Kessler Benzamide-Type AMPA Receptor Modulators Form Two Subfamilies with Distinct Modes of Action J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1075 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Arai, Y.-F. Xia, M. Kessler, D. Phillips, R. Chamberlin, R. Granger, and G. Lynch Effects of 5'-Alkyl-Benzothiadiazides on (R,S)-alpha -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Biophysics and Synaptic Responses Mol. Pharmacol., September 1, 2002; 62(3): 566 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lin, F. A. Brucher, L. L. Colgin, and G. Lynch Long-Term Potentiation Alters the Modulator Pharmacology of AMPA-Type Glutamate Receptors J Neurophysiol, June 1, 2002; 87(6): 2790 - 2800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Glavinovic Mechanisms Shaping Fast Excitatory Postsynaptic Currents in the Central Nervous System Neural Comput., January 1, 2002; 14(1): 1 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Gainetdinov, A. R. Mohn, L. M. Bohn, and M. G. Caron Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter PNAS, September 25, 2001; 98(20): 11047 - 11054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Baumbarger, M. Muhlhauser, J. Zhai, C. R. Yang, and E. S. Nisenbaum Positive Modulation of alpha -Amino-3-hydroxy-5-methyl-4-isoxazole Propionic Acid (AMPA) Receptors in Prefrontal Cortical Pyramidal Neurons by a Novel Allosteric Potentiator J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 86 - 102. [Abstract] [Full Text]
|
|
|
|
|
|
S. Lei, B. A. Orser, G. R. L. Thatcher, J. N. Reynolds, and J. F. MacDonald Positive Allosteric Modulators of AMPA Receptors Reduce Proton-Induced Receptor Desensitization in Rat Hippocampal Neurons J Neurophysiol, May 1, 2001; 85(5): 2030 - 2038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhao, A. Kuryatov, J. M. Lindstrom, J. Z. Yeh, and T. Narahashi Nootropic Drug Modulation of Neuronal Nicotinic Acetylcholine Receptors in Rat Cortical Neurons Mol. Pharmacol., April 1, 2001; 59(4): 674 - 683. [Abstract] [Full Text]
|
|
|
|
|
|
A. C. Arai, M. Kessler, G. Rogers, and G. Lynch Effects of the Potent Ampakine CX614 on Hippocampal and Recombinant AMPA Receptors: Interactions with Cyclothiazide and GYKI 52466 Mol. Pharmacol., October 1, 2000; 58(4): 802 - 813. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. Danysz and C. G. Parsons Glycine and N-Methyl-D-Aspartate Receptors: Physiological Significance and Possible Therapeutic Applications Pharmacol. Rev., December 1, 1998; 50(4): 597 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Gottschalk, L. D. Pozzo-Miller, A. Figurov, and B. Lu Presynaptic Modulation of Synaptic Transmission and Plasticity by Brain-Derived Neurotrophic Factor in the Developing Hippocampus J. Neurosci., September 1, 1998; 18(17): 6830 - 6839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Hampson, G. Rogers, G. Lynch, and S. A. Deadwyler Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Enhancement of Delayed-Nonmatch-to-Sample Performance J. Neurosci., April 1, 1998; 18(7): 2740 - 2747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nishizaki, T. Matsuoka, T. Nomura, K. Sumikawa, T. Shiotani, S. Watabe, and M. Yoshii Nefiracetam Modulates Acetylcholine Receptor Currents via Two Different Signal Transduction Pathways Mol. Pharmacol., January 1, 1998; 53(1): 1 - 5. [Abstract] [Full Text]
|
|
|
|
|
|
A. Pittaluga, D. Vaccari, and M. Raiteri The "Kynurenate Test," a Biochemical Assay for Putative Cognition Enhancers J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 82 - 90. [Abstract] [Full Text]
|
|
|
|
|
|
M. Sekiguchi, M. W. Fleck, M. L. Mayer, J. Takeo, Y. Chiba, S. Yamashita, and K. Wada A Novel Allosteric Potentiator of AMPA Receptors: 4-[2-(Phenylsulfonylamino)ethylthio]-2,6-Difluoro-Phenoxyacetamide J. Neurosci., August 1, 1997; 17(15): 5760 - 5771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Impagnatiello, A. Oberto, P. Longone, E. Costa, and A. Guidotti 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide: A partial modulator of AMPA receptor desensitization devoid of neurotoxicity PNAS, June 24, 1997; 94(13): 7053 - 7058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.H.P. Allen and A. Burns The treatment of Alzheimer's disease J Psychopharmacol, January 1, 1995; 9(1): 43 - 56. [PDF]
|
|
|
|
|
|
C. Ventra, M. Grimaldi, O. Meucci, A. Scorziello, A. Apicella, E. Filetti, A. Marino, and G. Schettini Aniracetam improves behavioural responses and facilitates signal transduction in the rat brain J Psychopharmacol, January 1, 1994; 8(2): 109 - 117. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
